Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LiveSpo Navax
- Development stage
- Unknown
- Lead developer
- LiveSpo Pharma
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intranasal
01
Overview
LiveSpo Navax is a nasal spray probiotic formulation containing spores of *Bacillus subtilis* and *Bacillus clausii*. Developed by AnaBio Technologies, it is designed for the prevention and supportive treatment of acute respiratory tract infections (ARTIs), including acute rhinosinusitis (ARS), acute otitis media (AOM), and infections caused by respiratory syncytial virus (RSV). The product delivers high concentrations of Bacillus spores directly to the nasal mucosa, where they germinate into vegetative cells that compete with pathogenic microorganisms for adhesion sites and nutrients. This microbial competition, combined with the secretion of antimicrobial substances and modulation of the local immune response, helps to reduce inflammation and viral load in the respiratory tract. A lower-concentration variant, LiveSpo Navax Kid, is specifically formulated for pediatric use.
- Brand names
- LiveSpo NavaxLiveSpo Navax Kid
- Other names
- Bacillus subtilis + Bacillus clausii nasal spray
Beyond the preview
Go deeper on LiveSpo Navax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LiveSpo Navax.